These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9037283)

  • 1. Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs.
    Matchar DB; McCrory DC; Bennett CL
    Urology; 1997 Feb; 49(2):218-24. PubMed ID: 9037283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
    Bennett CL; Matchar D; McCrory D; McLeod DG; Crawford ED; Hillner BE
    Cancer; 1996 May; 77(9):1854-61. PubMed ID: 8646685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer.
    Hillner BE; McLeod DG; Crawford ED; Bennett CL
    Urology; 1995 Apr; 45(4):633-40. PubMed ID: 7716844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicians' perceived knowledge of and responsibility for managing patients' out-of-pocket costs for prescription drugs.
    Shrank WH; Asch SM; Joseph GJ; Young HN; Ettner SL; Kholodenko Y; Glassman P; Kravitz RL
    Ann Pharmacother; 2006 Sep; 40(9):1534-40. PubMed ID: 16912246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
    Lloyd A; Penson D; Dewilde S; Kleinman L
    Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians.
    Bennett CL; Chapman G; Elstein AS; Knight SJ; Nadler RB; Sharifi R; Kuzel T
    Eur Urol; 1997; 32 Suppl 3():86-8. PubMed ID: 9267792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
    Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
    Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
    Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L;
    Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate?
    Datta SN; Thomas K; Matthews PN
    J Urol; 1997 Jul; 158(1):175-7. PubMed ID: 9186348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients.
    Potosky AL; Merrill RM; Riley GF; Taplin SH; Barlow W; Fireman BH; Lubitz JD
    Health Serv Res; 1999 Jun; 34(2):525-46. PubMed ID: 10357289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician consideration of patients' out-of-pocket costs in making common clinical decisions.
    Pham HH; Alexander GC; O'Malley AS
    Arch Intern Med; 2007 Apr; 167(7):663-8. PubMed ID: 17420424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.
    Sadetsky N; Lubeck DP; Pasta DJ; Latini DM; DuChane J; Carroll PR
    BJU Int; 2008 Mar; 101(6):691-7. PubMed ID: 18291018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.